The innovative small molecule drug toxicokinetic test platform featuring high sensitivity and specificity based on UPLC-MS/MS has been established for high-throughput, high-precision, high-efficiency, automation and trace-level research and technical services of chemical drugs and biological products (small molecular target drugs such as small peptides and small nucleic acids, etc.); the platform is capable of testing 2500 GLP samples per day in support of rapid transformation of innovative drug discoveries. Additionally, in vivo detection techniques have been established in line with international standards for antibody drugs, gene therapy drugs and cell therapy drugs. The platform is equipped with facilities and technical capabilities to analyze and determine the concentration of multiple bio-tech drugs in vivo simultaneously.
The innovative small molecule drug toxicokinetic test platform featuring high sensitivity and specificity based on UPLC-MS/MS has been established for high-throughput, high-precision, high-efficiency, automation and trace-level research and technical services of chemical drugs and biological products (small molecular target drugs such as small peptides and small nucleic acids, etc.);
The platform is capable of testing 2500 GLP samples per day in support of rapid transformation of innovative drug discoveries.
All bioanalytical researchers are adequately experienced in the analysis of small molecules (including chiral compounds) and peptides and knowledgeable of applicable regulations on bioanalysis.
Techniques have been established in line with international standards for in vivo testing of bio-tech drugs such as antibodies, proteins, gene and cell therapy drugs; our facility scale and technical capabilities are adequate for determining the in vivo concentration of multiple bio-tech drugs and anti-drug antibodies simultaneously.
Antibody drugs
Antibody drugs：more than 30 targets, including PD-1, PD-L1, VEGF, and SARS-CoV-2
Types of bispecific antibodies：more than 20 types, including PD1-PD-L1, etc.
ADC drugs
Nanobodies
Tertiary antibodies
Peptide and hormone drugs
rhBNP, rhNGF, ABWT, rhPTH(1-34), PEG-GLP-1, PEG-IFN-β, PEG-Uricase, PEGylated recombinant human granulocyte-colony stimulating factor, peptide-drug conjugate(PDG) drugs, etc.
Fusion protein drugs
rhGH-Fc, VEGFR-Fc, GLP-1-Fc, rhEPO-Fc, IL-2-Fc, VIIa-Fc, etc.
Cell therapy drugs
HuRPE (human-derived retinal pigment epithelia)
Human umbilical cord-derived/placenta-derived mesenchymal stem cells
Car-NK
Gene therapy drugs
rAAV vector drugs
Oncolytic viruses
Plasmid vectors
Others
Human hemoglobin (Hb), COVID-19 vaccines, hepatitis A vaccines, 6-valent Group B streptococcal polysaccharide conjugate vaccines, etc.
+8628-60662518-8800
+8628-85154334-800
E-mail：service@glpcd.com
Monday to Friday 9:00-17:30
Consultation-hotline
Privacy ClauseLegal StatementWebsite MapWestChina-Frontier PharmaTech Co., Ltd. © All rights reserved 蜀ICP备11014334-1号 川公网安备51019002003861号
